Document:

Document

Exhibit 10.2

EXECUTION COPY

CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

AMENDMENT NO. 3 TO
MARKET ACCESS SERVICES AGREEMENT

This Amendment No. 3 (this “Amendment”) is entered into as of March 15, 2021 (the “Amendment Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Myovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).

A.Sunovion and Myovant entered into that certain Market Access Services Agreement dated August 1, 2020 (the “Agreement”); and

B.Sunovion and Myovant desire to amend certain rights and obligations under the Agreement regarding (i) certain RCP Services, and (ii) add the definition of Specialty Pharmacy to the Agreement.

THEREFORE, in consideration of the mutual covenants and promises contained herein, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound hereby, it is understood and agreed upon by and between the Parties as follows:

1.AMENDMENTS

1.The following is added to the definitions section as 1.93.1:

“Specialty Pharmacy” means [***], and any other specialty pharmacies as contracted with from time to time.

2.Section 4.6 RCP Services of the Agreement is deleted in its entirety and replaced with the following:

“RCP Services. Sunovion, subject to Section 4.1 and 4.3.2 (as Section 4.3.2 relates to the Prostate Cancer Product), shall perform the RCP Services. Notwithstanding the foregoing, Myovant shall be responsible for performing the RCP Services listed in section 4.6.1 herein.”

3.The following is added as section 4.6.1 to the Agreement:

“4.6.1 RCP Services for [***] shall be performed by Myovant inclusive of invoice validation, processing and payment.”

4.Exhibit E of the Agreement is deleted in its entirety and replaced with Attachment 1 to this Amendment titled Exhibit E.

Confidential & Proprietary

2.MISCELLANEOUS

2.1Entire Agreement. This Amendment, together with the Agreement, constitutes the entire agreement between the Parties with respect to the specific subject matter of the Agreement and supersedes all other prior negotiations, discussions, agreements or understandings, whether written or oral, with respect to the subject matter the Agreement. In the event of a conflict between this Amendment and the Agreement, this Amendment shall prevail.

2.2Counterparts. This Amendment may be executed in any number of counterparts, each of which will be deemed to be an original, and all of which together will constitute one and the same instrument.

[Signature Page to Follow]

Confidential & Proprietary
Page 2

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed in duplicate by their duly authorized representatives, effective as of the Amendment Effective Date.

Sunovion Pharmaceuticals Inc.    Myovant Sciences GmbH

By: /s/ Thomas Gibbs        By: /s/ Viatcheslav Rakov            

Name: Thomas Gibbs        Name: Viatcheslav Rakov            

Title: SVP and Chief Commercial Officer        Title: VP Medial Clinical                

Confidential & Proprietary

[Signature Page to Amendment No. 3 to the Market Access Services Agreement]

ATTACHMENT 1

EXHIBIT E — RCP SERVICES

RCP Services shall include the following obligations with respect to the Products:

1.RCP Payment Validation. With the exception of the RCP Services listed in section 4.6.1, Sunovion shall validate all invoices for RCP Payments received from Market Access Customers, GPOs, IDNs, Wholesalers, Specialty Distributors, 3PL Providers, and Government Entities to ensure such invoices are consistent with the terms and conditions of the applicable contract and apply to eligible utilization of the applicable Products only, using a validation process agreed upon in writing by the Parties.

2.RCP Payment Administration. With the exception of the RCP Services listed in section 4.6.1, Sunovion shall process and pay, using funds from the Escrow Fund and pursuant to the terms and conditions of the applicable contract, all validated RCP Payments.Document

    

Exhibit 10.3
CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

AMENDMENT NO. 4
TO 
MARKET ACCESS SERVICES AGREEMENT
This Amendment No. 4 (this “Amendment”) is entered into as of August 9, 2022 (the “Amendment Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Myovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).
RECITALS
 
A.Sunovion and Myovant entered into that certain Market Access Services Agreement dated August 1, 2020 and amended as of December 14, 2020, January 25, 2021, March 15, 2021 and August 9, 2022 (collectively, the “Agreement”); 
B.Sunovion and Myovant acknowledge and agree the amendment titled “Amendment No. 1 to Market Access Services Agreement” to the Agreement entered into by and between the parties effective December 14, 2020 is the first amendment to the Agreement;
C.Sunovion and Myovant acknowledge and agree the amendment titled “Amendment No. 2 to Market Access Services Agreement” entered into by and between the parties effective January 25, 2021 is the second amendment to the Agreement;
D.Sunovion and Myovant acknowledge and agree the amendment titled “Amendment No. 3 to Market Access Services Agreement” entered into by and between the parties effective March 15, 2021 is the third amendment to the Agreement;
E.Sunovion and Myovant acknowledge and agree the amendment titled “Amendment No. 3 to Market Access Services Agreement” entered into by and between the parties effective August 9, 2022 and attached hereto as Attachment 1, is the fourth amendment to the Agreement and due to a scrivener’s error was mislabeled as the third amendment to the Agreement; and
F.Sunovion and Myovant acknowledge and agree that references to “Amendment No. 4 to the Market Access Services Agreement” shall include both (i) the amendment titled “Amendment No. 3 to Market Access Services Agreement” entered into by and between the parties effective August 9, 2022 and (ii) this Amendment.  
THEREFORE, in consideration of the mutual covenants and promises contained herein, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound hereby, it is understood and agreed upon by and between the parties the Recitals to this Amendment are incorporated into and shall constitute a part of the Agreement.

[Signatures to follow on next page.]
    Page 1 of 3    
Confidential & Proprietary        

    

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized representatives to be effective as of the Amendment Effective Date.  

Sunovion Pharmaceuticals Inc.            Myovant Sciences GmbH
                        
    
By: /s/ Lisa Mullett                By: /s/ Matthew Lang            

Print Name: Lisa Mullett                Print Name: Matthew Lang        

Title: Chief Commercial Officer            Title: General Manager            
    
                

    Page 2 of 3    
Confidential & Proprietary        

    

ATTACHMENT 1

    Page 3 of 3    
Confidential & Proprietary        

    

AMENDMENT NO. 3
TO 
MARKET ACCESS SERVICES AGREEMENT
This Amendment No. 3 (this “Amendment”) is entered into as of August 9, 2022 (the “Amendment Effective Date”) by and between Sunovion Pharmaceuticals Inc., a Delaware corporation, having a principle place of business at 84 Waterford Drive, Marlborough, MA 01752 (“Sunovion”) and Myovant Sciences GmbH, a Swiss corporation, having a principle place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Myovant”). Capitalized terms used in this Amendment that are not defined in this Amendment shall have the meaning set forth in the Agreement (as defined below).
RECITALS
 
A.Sunovion and Myovant entered into that certain Market Access Services Agreement dated August 1, 2020 and amended as of December 14, 2020 and January 25, 2021 (collectively, the “Agreement”); and 

B. Sunovion and Myovant desire to amend certain rights and obligations under the Agreement regarding the Monthly Flat Service Charge

THEREFORE, in consideration of the mutual covenants and promises contained herein, and for good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, intending to be legally bound hereby, it is understood and agreed upon by and between the Parties as follows:

1.AMENDMENTS

1.1    Section 1.59 of the Agreement is hereby deleted in its entirety and replaced as follows: 

““Monthly Flat Service Charge” means, subject to Section 8.2.2, (i) [***] per calendar month [***], and (ii) an adjusted amount for each year after [***] consistent with Section 8.2.2; provided that, (i) if a contract year begins after the first day of a calendar month, such amount shall be multiplied by a fraction where the numerator is the number of days in such calendar month that are on or after first day of the contract year and the denominator is the number of days in such calendar month, and (ii) if a contract year ends before the last day of a calendar month, such amount shall be multiplied by a fraction where the numerator is the number of days in such calendar month that are on or before the last day of the contract year and the denominator is the number of days in such calendar month.”

2.MISCELLANEOUS

2.1    Entire Agreement. This Amendment, together with the Agreement, constitutes the entire agreement between the Parties with respect to the specific subject matter of the Agreement and supersedes all other prior negotiations, discussions, agreements or

     
    Page 1 of 3    
Confidential & Proprietary        

    

understandings, whether written or oral, with respect to the subject matter the Agreement. In the event of a conflict between this Amendment and the Agreement, this Amendment shall prevail.

2.2    Counterparts. This Amendment may be executed in any number of counterparts, each of which will be deemed to be an original, and all of which together will constitute one and the same instrument.
 

[Signatures to follow on next page.]
    Page 2 of 3    
Confidential & Proprietary        

    

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized representatives to be effective as of the Amendment Effective Date.  

Sunovion Pharmaceuticals Inc.            Myovant Sciences GmbH
                        
    
By: /s/ Lisa Mullett                By: /s/ Viatcheslav Rakov            

Print Name: Lisa Mullett                Print Name: Viatcheslav Rakov        

Title: Chief Commercial Officer, Interim        Title: VP Medical - Clinical        
    
                

    Page 3 of 3    
Confidential & Proprietary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]